• CEO interview: Growth Strategy of Shionogi

What's New

  • Show All
2019/02/20
Notice Regarding Completion of Cancellation of Treasury Shares (Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act)
2019/02/20
Our Goal Through Strategic Collaboration with SAGE (February 5, 2019)
2019/02/19
SHIONOGI to Announce Corporate Reorganization and Personnel Reassignment
2019/02/08
Audio webcasting: Third Quarter of FY2018 Financial Results
2019/01/31
Financial Results for the Third Quarter of FY2018
2019/01/31
Notice Regarding Changes of Cancellation of Treasury Shares(Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act)
2019/01/23
Shionogi Announces Agreements on Collaborative Research with PeptiDream for New Peptide Drug Conjugate (PDC) Discovery
2018/12/21
Notice Regarding the Status and Completion of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
2018/12/19
Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commercialization
2018/12/18
Shionogi Receives Positive Opinion for Lusutrombopag in Latest Announcement from the Committee for Medicinal Products for Human Use (CHMP)
2018/12/18
Shionogi Receives Positive Opinion for Rizmoic (naldemedine) in Latest Announcement from the Committee for Medicinal Products for Human Use (CHMP)
2018/12/14
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
2018/12/10
SHIONOGI and Ube Industries Entered into Strategic Research Collaboration for Novel Anti-RS Virus Drug Candidates